Search Results - "BOWCOCK, S"

Refine Results
  1. 1

    A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy by Fortune, D.G., Richards, H.L., Kirby, B., Bowcock, S., Main, C.J., Griffiths, C.E.M.

    Published in British journal of dermatology (1951) (01-03-2002)
    “…Summary Background Patients with psoriasis may experience significant psychological and social disabilities. Stress or distress are proposed aggravators of the…”
    Get full text
    Journal Article
  2. 2

    Repeat haematinic requests in patients with previous normal results: the scale of the problem in elderly patients at a district general hospital by GANIYU-DADA, Z., BOWCOCK, S.

    “…Summary Repeating normal laboratory tests can waste resources. This study aimed to quantify unnecessary repeat haematinic tests taken from the elderly in a…”
    Get full text
    Journal Article
  3. 3

    United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma by Pratt, G., Bowcock, S., Lai, M., Bell, S., Bird, J., D'Sa, S., Cavenagh, J., Cook, G., Morgan, G., Owen, R., Snowden, J.A., Yong, K., Davies, F.

    “…Summary Bendamustine is a unique bifunctional alkylating agent with promising activity in myeloma. Despite the increasing number of studies demonstrating its…”
    Get full text
    Journal Article
  4. 4

    United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma by Rabin, N., Lai, M., Pratt, G., Morgan, G., Snowden, J., Bird, J., Cook, G., Bowcock, S., Owen, R., Yong, K., Wechalaker, A., Low, E., Davies, F.

    “…Summary Therapeutic advances and the availability of novel agents have significantly improved outcomes in myeloma; yet, it remains incurable and strategies to…”
    Get full text
    Journal Article
  5. 5

    Optical properties of solid-core photonic crystal fibers filled with nonlinear absorbers by Butler, James J, Bowcock, Alec S, Sueoka, Stacey R, Montgomery, Steven R, Flom, Steven R, Friebele, E Joseph, Wright, Barbara M, Peele, John R, Pong, Richard G S, Shirk, James S, Hu, Jonathan, Menyuk, Curtis R, Taunay, T F

    Published in Optics express (09-09-2013)
    “…A theoretical and experimental investigation of the transmission of solid-core photonic crystal fibers (PCFs) filled with nonlinear absorbers shows a sharp…”
    Get full text
    Journal Article
  6. 6

    Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection by Cheingsong-Popov, R, Panagiotidi, C, Bowcock, S, Aronstam, A, Wadsworth, J, Weber, J

    Published in BMJ (05-01-1991)
    “…OBJECTIVE--To study the contribution of the humoral response to HIV-I at seroconversion to disease outcome after 84 months. DESIGN--A retrospective…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9

    A prospective study of the incidence of delayed haemolytic transfusion reactions following peri-operative blood transfusion by Hewitt, P E, Macintyre, E A, Devenish, A, Bowcock, S J, Contreras, M

    Published in British journal of haematology (01-08-1988)
    “…Delayed haemolytic transfusion reactions (DHTRs) are a recognized sequel of blood transfusion. The true incidence and importance of this complication have been…”
    Get more information
    Journal Article
  10. 10

    Changes in blood flow close to subcutaneous insulin injection sites in stable and brittle diabetics by Williams, G., Pickup, J., Clark, A., Bowcock, S., Cooke, E., Keen, H.

    Published in Diabetes (New York, N.Y.) (01-05-1983)
    “…Changes in blood flow close to subcutaneous insulin injection sites in stable and brittle diabetics. G Williams , J Pickup , A Clark , S Bowcock , E Cooke and…”
    Get full text
    Journal Article
  11. 11

    Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis by Meyrick Thomas, R H, Rademaker, M, Grimes, S M, MacKay, A, Kovacs, I B, Cook, E D, Bowcock, S M, Kirby, J D

    Published in British journal of dermatology (1951) (01-08-1987)
    “…A double-blind, placebo-controlled, cross-over trial of nifedipine 10 mg three times daily for 6 weeks, in 10 patients with Raynaud's phenomenon secondary to…”
    Get more information
    Journal Article
  12. 12

    U nited K ingdom M yeloma F orum ( UKMF ) position statement on the use of bendamustine in myeloma by Pratt, G., Bowcock, S., Lai, M., Bell, S., Bird, J., D'Sa, S., Cavenagh, J., Cook, G., Morgan, G., Owen, R., Snowden, J.A., Yong, K., Davies, F.

    “…Bendamustine is a unique bifunctional alkylating agent with promising activity in myeloma. Despite the increasing number of studies demonstrating its efficacy…”
    Get full text
    Journal Article
  13. 13

    Marrow aplasia developing 3 years after treatment with busulphan for chronic myeloid leukaemia by Bowcock, S J, Galton, D A, Goldman, J M

    Published in European journal of haematology (01-05-1989)
    “…A 31-year-old woman with Philadelphia chromosome-positive chronic myeloid leukaemia (CML) was treated intermittently with high-dose busulphan over a 6-yr…”
    Get more information
    Journal Article
  14. 14

    Cold sensitivity in essential hypertension: the effect of beta-and combined alpha- and beta-blockade by COOKE, E. D, BOWCOCK, S. A, SMITH, A. T

    “…The presence of cold sensitivity was investigated in three groups of patients; untreated hypertensives and hypertensives treated by a beta-adrenoceptor blocker…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Pyrimethamine in the myeloproliferative disorders: a forgotten treatment? by Bowcock, S J, Linch, D C, Machin, S J, Stewart, J W

    Published in Clinical and laboratory haematology (01-01-1987)
    “…Eight patients with myeloproliferative disorders, five with polycythaemia rubra vera (PRV) and three with essential thrombocythaemia (ET), have been treated…”
    Get more information
    Journal Article
  17. 17

    Peripheral vascular effects of beta‐adrenoceptor blockade: comparison of two agents by Cooke, ED, Maltz, MB, Smith, RE, Bowcock, SA, Watkins, CJ, Camm, AJ

    Published in British journal of clinical pharmacology (01-09-1987)
    “…1. The effects of atenolol (100 mg), a beta 1‐adrenoceptor blocker, and bevantolol (200 mg) were compared on heart rate, blood pressure, lung function and on…”
    Get full text
    Journal Article
  18. 18
  19. 19

    A double blind trial of UK-38,485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome by RUSTIN, M. H. A, GRIMES, S. M, KOVACS, I. B, COOKE, E. D, BOWCOCK, S. A, SOWEMIMO-COKER, S. O, TURNER, P, KIRBY, J. T. D

    Published in European journal of clinical pharmacology (01-01-1984)
    “…Ten patients with moderate to severe Raynaud's syndrome were recruited into a four week randomised double blind crossover study to compare the efficacy of…”
    Get full text
    Journal Article
  20. 20

    Subcutaneous aprotinin causes local hyperaemia. A possible mechanism by which aprotinin improves control in some diabetic patients by Williams, G, Pickup, J C, Bowcock, S, Cooke, E, Keen, H

    Published in Diabetologia (01-02-1983)
    “…Local changes in blood flow at the subcutaneous injection site of the proteinase inhibitor aprotinin and its diluent were measured by photoelectric…”
    Get full text
    Journal Article